{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:35:18Z","timestamp":1787646918371,"version":"build-2736575974"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.3242","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T11:44:51Z","timestamp":1556883891000},"page":"e193242","source":"Crossref","is-referenced-by-count":58,"title":["Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products"],"prefix":"10.1001","volume":"2","author":[{"given":"Marcus","family":"Shaker","sequence":"first","affiliation":[{"name":"Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Lebanon, New Hampshire"},{"name":"Dartmouth Geisel School of Medicine, Hanover, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Greenhawt","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Colorado, University of Colorado School of Medicine, Section of Allergy and Immunology, Food Challenge and Research Unit, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"issue":"21","key":"zoi190142r3","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy.","volume":"379","author":"Vickery","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi190142r4","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1001\/jama.2017.16591","article-title":"Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial.","volume":"318","author":"Sampson","year":"2017","journal-title":"JAMA"},{"key":"zoi190142r5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jama.2019.1113","article-title":"Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial.","volume":"321","author":"Fleischer","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"zoi190142r6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaip.2017.05.006","article-title":"Quantitative assessment of the safety benefits associated with increasing clinical peanut thresholds through immunotherapy.","volume":"6","author":"Baumert","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"zoi190142r7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jaci.2016.01.001","article-title":"Food allergen immunotherapy: current status and prospects for the future.","volume":"137","author":"Wood","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"zoi190142r8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.anai.2018.06.018","article-title":"Understanding caregiver goals, benefits, and acceptable risks of peanut allergy therapies.","volume":"121","author":"Greenhawt","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"zoi190142r9","doi-asserted-by":"publisher","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"zoi190142r10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaci.2017.11.003","article-title":"Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management.","volume":"141","author":"Sicherer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"zoi190142r11","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/all.2017.72.issue-8","article-title":"Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis.","volume":"72","author":"Nurmatov","year":"2017","journal-title":"Allergy"},{"issue":"12","key":"zoi190142r12","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/cea.12211","article-title":"Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta-analysis.","volume":"43","author":"Umasunthar","year":"2013","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"zoi190142r13","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jaip.2017.04.016","article-title":"An economic analysis of a peanut oral immunotherapy study in children.","volume":"5","author":"Shaker","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"zoi190142r14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.anai.2017.05.020","article-title":"Economic evaluation of epinephrine auto-injectors for peanut allergy.","volume":"119","author":"Shaker","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"zoi190142r15","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaip.2017.06.031","article-title":"Fatal anaphylaxis: mortality rate and risk factors.","volume":"5","author":"Turner","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"zoi190142r16","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.jaip.2018.04.036","article-title":"The health and economic outcomes of peanut allergy management practices.","volume":"6","author":"Shaker","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"zoi190142r17","doi-asserted-by":"publisher","first-page":"e184728","DOI":"10.1001\/jamanetworkopen.2018.4728","article-title":"Association of fatality risk with value-based drug pricing of epinephrine autoinjectors for children with peanut allergy: a cost-effectiveness analysis.","volume":"1","author":"Shaker","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi190142r18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.anai.2018.06.035","article-title":"Economic outcomes of immediate activation of emergency medical services after epinephrine use for peanut-induced anaphylaxis.","volume":"122","author":"Shaker","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"zoi190142r19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/jamapediatrics.2018.4275","article-title":"Analysis of value-based costs of undesignated school stock epinephrine policies for peanut anaphylaxis.","volume":"173","author":"Shaker","year":"2019","journal-title":"JAMA Pediatr"},{"issue":"5","key":"zoi190142r20","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.jaci.2014.05.013","article-title":"Food allergy: a practice parameter update-2014.","volume":"134","author":"Sampson","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"zoi190142r21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpeds.2009.01.040","article-title":"Improving decision analyses: parent preferences (utility values) for pediatric health outcomes.","volume":"155","author":"Carroll","year":"2009","journal-title":"J Pediatr"},{"issue":"9925","key":"zoi190142r22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/S0140-6736(13)62301-6","article-title":"Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.","volume":"383","author":"Anagnostou","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"zoi190142r23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/pai.12337","article-title":"Health-related quality of life in children with perceived and diagnosed food hypersensitivity.","volume":"26","author":"Venter","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"issue":"5","key":"zoi190142r24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.anai.2011.11.010","article-title":"The natural history of persistent peanut allergy.","volume":"108","author":"Neuman-Sunshine","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"zoi190142r26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jaci.2015.01.002","article-title":"Natural history of peanut allergy and predictors of resolution in the first 4 years of life: a population-based assessment.","volume":"135","author":"Peters","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"zoi190142r27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1067\/mai.2001.112129","article-title":"The natural history of peanut allergy.","volume":"107","author":"Skolnick","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"zoi190142r29","first-page":"S2213-2198(18)30748-7","article-title":"Accidental versus new food allergy reactions in a pediatric emergency department.","author":"Capucilli","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"zoi190142r30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","article-title":"Anaphylaxis\u2014a practice parameter update 2015.","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"zoi190142r31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.anai.2017.06.001","article-title":"Factors associated with epinephrine administration for anaphylaxis in children before arrival to the emergency department.","volume":"119","author":"Robinson","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"zoi190142r32","first-page":"1","article-title":"United States life tables, 2013.","volume":"66","author":"Arias","year":"2017","journal-title":"Natl Vital Stat Rep"},{"issue":"11","key":"zoi190142r33","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1001\/jamapediatrics.2013.2376","article-title":"The economic impact of childhood food allergy in the United States.","volume":"167","author":"Gupta","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"1","key":"zoi190142r37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2011.03.013","article-title":"Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States.","volume":"128","author":"Patel","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"zoi190142r38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/027298902320556118","article-title":"Health economic evaluations: the special case of end-stage renal disease treatment.","volume":"22","author":"Winkelmayer","year":"2002","journal-title":"Med Decis Making"},{"issue":"11","key":"zoi190142r40","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1111\/cea.2015.45.issue-11","article-title":"Incidence of food anaphylaxis in people with food allergy: a systematic review and meta-analysis.","volume":"45","author":"Umasunthar","year":"2015","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"zoi190142r41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/pai.2018.29.issue-5","article-title":"Long-term outcome of peanut oral immunotherapy\u2014real-life experience.","volume":"29","author":"Nachshon","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"zoi190142r25","author":"Greenhawt","year":"2018"},{"key":"zoi190142r28","volume-title":"Finding a Path to Safety in Food Allergy: Assessment of the Global Burden, Causes, Prevention, Management, and Public Policy","author":"Oria","year":"2016"},{"key":"zoi190142r1","unstructured":"DBV Technologies announces submission of biologics license application for Viaskin Peanut to the U.S. Food and Drug Administration [press release]. Montrouge, France: DBV Technologies; October 22, 2018. https:\/\/www.dbv-technologies.com\/wp-content\/uploads\/2018\/10\/pr-bla-submission-102218-final.pdf. Accessed December 11, 2018."},{"key":"zoi190142r2","unstructured":"Aimmune Therapeutics announces new clinical data on AR101 for peanut allergy at the 2018 EAACI Congress [press release]. Brisbane, CA: Aimmunie Therapeutics; May 28, 2018. http:\/\/ir.aimmune.com\/news-releases\/news-release-details\/aimmune-therapeutics-announces-new-clinical-data-ar101-peanut. Accessed December 11, 2018."},{"key":"zoi190142r34","unstructured":"Healthcare Bluebook. https:\/\/www.healthcarebluebook.com. Accessed October 8, 2017."},{"key":"zoi190142r35","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched\/index.html. Accessed October 3, 2017."},{"key":"zoi190142r36","unstructured":"US Department of Labor, Bureau of Labor Statistics. http:\/\/www.bls.gov. Accessed September 28, 2017."},{"key":"zoi190142r39","unstructured":"Associated Press. Correction: peanut allergy treatment story. https:\/\/www.apnews.com\/18cbf4b4479e4093b9d062a4430658e9. Accessed February 25, 2018."},{"key":"zoi190142r42","unstructured":"Duke Margolis Center for Health Policy. Developing a path to value-based payment for medical products: value-based payment advisory group kick-off meeting. https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/atoms\/files\/value_based_payment_background_paper_-_october_2017_final.pdf. Accessed March 10, 2019."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/2\/5\/e193242\/17553003\/shaker_2019_oi_190142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T11:44:55Z","timestamp":1556883895000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2019.3242"}},"subtitle":["A Cost-effectiveness Analysis"],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.3242","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]}}}